Case

Oncology Phase 3 Probability of Success Predictor

Challenge

More than half of Phase 3 oncology trials fails.

Solution

Forward-looking predictions of Phase 3 success to identify high- and low-risk trials.

Impact

Overall accuracy of >70% enables applications in R&D portfolio management and capital allocation.

Client

Research collaboration with Catenion, a strategy consultancy with the largest team exclusively focused on Biopharma R&D.